Efficacy and safety of upadacitinib in the treatment of moderate to severe atopic dermatitis

A prospective, randomized, controlled, single-centre phase ? clinical trial to evaluate the efficacy and safety of upadacitinib in patients aged 12 to 75 years with moderate to severe atopic dermatitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063335

Enrollment

Unknown

Registered

2022-09-04

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

experimental group:Upadacitinib + TCS

control group:Cyclosporine +TCS

Eligibility

Sex/Gender

All

Age

12 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with moderate to severe atopic dermatitis aged 12–75 years; 2. Duration of AD >= half a year; 3. EASI >= 16, and vIGA-AD >= 3; 4. Weekly average WP-NRS >= 4.

Exclusion criteria

Exclusion criteria: 1. Age 75 years old; 2. Those who are allergic to the active ingredients of Upatinib or any excipients; 3. Active tuberculosis or active serious infection; 4. Severe liver damage; 5. Pregnancy population.

Design outcomes

Primary

Measure	Time frame
respond of EASI 75 at 16 week;respond of EASI 90 at 16 week;	—

Secondary

Measure	Time frame
Adverse Drug Reactions at Weeks 1, 2, 4, 8, 12, and 16;Proportion of patients with EASI 75% and EASI 90% at weeks 0, 1, 2, 4, 8, 12;Proportion of patients with WP-NRS improvement =4 at weeks 0, 1, 2, 4, 8, 12, and 16;;	—

Countries

China

Contacts

Public ContactLin Dang

Longgang district Central Hospital

dang1555@qq.com+86 13528857409

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026